Expression Of MiR-135a In Myelodysplastic Syndromes And Acute Myeloid Leukemia Patients And The Analysis Of Its Relationship To C-myc

Objective Myelodysplastic syndromes (MDS), characterized by ineffectivehematopoiesis and dysplasia in one or more lineages, produce life-threateningcytopenias and progress to acute myeloid leukemia (AML).Acute myeloid leukemia(AML), also known as acute myelogenous leukemia or acute nonlymphocyticleukemia (ANLL), is a cancer of the myeloid line of blood cells, characterized by therapid growth of abnormal white blood cells that accumulate in the bone marrow andinterfere with the production of normal blood cells. Growing evidence suggests thatmiR-135a was involed in the development of vrious diseases. The c-myc gene is awell-characterized proto-oncogene and that deregulation of this protein is observed innumerous cancers include MDS and AML. Previous research has shown that c-mycwas the target gene of miR-135a.We investigate the expression of miR-135a inmyelodysplastic syndrome and acute myeloid leukemia patients.The relationshipbetween the expression of miR-135a and c-myc and clinical pathologicparameters in the MDS and AML was analysed.Methods1.42AML patients,19MDS patients and16normal subjects wascollected from department of Hematology of Fujian Medical University UnionHospital during January2013to February2014, previously untreated AML patientsincluding25males and17females, aged16-80years old, with a median age of48.5years old;19cases of MDS patients including11males and8females, aged27-74years old, with a median age of59years old.2. We collect the mononuclear cells ofbone marrowï¼› extract total RNA and reverse transcriptaseï¼›and expression ofmiR-135a was detected by real-time fluorescent quantitative reverse transcriptasepolymerase chain reaction (Realtime qPCR) while snU6RNA wan taken as an internalreference.Then we detected c-myc in the bone marrow biopsy sections of27AMLand16MDS by IHC. The relationship between the expression of miR-135a and c-myc was analysed.Results1. Expression of miR-135a in de novo AML and MDS were significantly lowerthan those in the normal control group, the difference was statistically significant.There is no statistically significant difference between expression of miR-135a inAML and MDS.2. Expression of miR-135a in all experimental groups and the control group have nostatistically significant relationship to age, gender, peripheral blood leukocyte count,hemoglobin, platelet count, FAB group and chromosome.3.The c-myc located in the nucleus and there is no significant correlation betweenexpression of c-myc and miR-135a in the AML and MDS patients.Conclusion Low expression of miR-135a in AML and MDS patients may play animportant role in the development of this two disease.In this study,there is noevidence show that miR-135a could regulate the expression of c-myc in the MDSand AML.